LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a)
07-04-10 kl. 7/4 2010 23:49 | Veloxis Pharmaceuticals 0,90 (+4,65%)
Se flere nyheder om Veloxis Pharmaceuticals
Company Announcement no. 6/2010
To: NASDAQ OMX Copenhagen Hørsholm, Denmark, April 7, 2010
LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act,
Section 28(a)
Hørsholm, Denmark, April 7, 2010; Pursuant to the Danish Securities Trading
Act, Section 28(a), LifeCycle Pharma A/S (OMX: LCP) is required on a daily
basis, to make public transactions in LifeCycle Pharma shares and related
securities by persons discharging managerial responsibilities and persons /
companies closely associated with these.
Name Timothy C. Melkus
Reason for reporting Senior Vice President, Development Operations
Issuer and ID code/ISIN LifeCycle Pharma A/S / DK0060048148
Type of transaction Purchase of shares
Date of transaction April 6, 2010
Relevant market NASDAQ OMX Copenhagen
Number of traded securities 100,000
Market value DKK 535,000
For more information, please contact:
LifeCycle Pharma A/S
Peter Schøtt Knudsen
Head of Investor Relations
Phone: + 45 2055 3817
Email: [email protected]
07 april 2010 - lifecycle pharma - report pursuant to the danish securities trading act section 28_a_.pdf
Skriv en kommentarer til denne artikel:
Send kommentar
| PRIS | 0,90 |
|---|---|
| ÆNDRING | +0,04 (+4,65%) |
| ÅBEN | 0,87 |
| SIDSTE LUK | 0,86 |
| DEBAT | - |
 |
